Skymark Research Initiates Independent Research Coverage on MabCure, Inc.
July 29 2010 - 9:15AM
Skymark Research, a leading provider of small- and micro-cap
independent investment research, today initiated coverage on
MabCure, Inc. (OTCBB:MBCI).
Skymark Research is currently offering a complimentary trial
subscription. To view our research go to:
www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment
research in North America. Our services include research
analysis on the small- and micro-cap markets, real-time news and
financial data, market commentary and the SMR newsletter. Skymark
Research's staff of small-cap investment professionals is dedicated
to providing the small market's investment community with the tools
and avenues necessary to make the important investment
decisions. To view our research reports on a complimentary
trial basis and take advantage of our other services, go to
www.skymarkresearch.com and click on the complimentary trial
subscription button on our home page, or go directly to our
registration page at www.skymarkresearch.com/signup.php.
The Skymark Research logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6683
About MabCure, Inc. (OTCQB:MBCI):
MabCure, Inc. (OTCBB:MBCI) is a development stage company.
The Company is engaged in the business of developing and
commercializing its antibody technology for the early detection of
cancer and for the creation of therapeutics (antibodies and drugs)
against cancer.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. Skymark
Research has not been compensated by any of the above mentioned
companies. Please read our report and visit our Web site,
www.skymarkresearch.com, for complete risks and disclosures.
CONTACT: Skymark Research
Dylan Boyle
480-626-1911
info@skymarkresearch.com
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jul 2023 to Jul 2024